Gabrielle’s Angel Foundation funds cutting-edge research in the fields of leukemia, lymphoma, and related cancers of the blood.

We support research that focuses on cancer prevention, detection, and treatments that are most likely to be translated into clinical trials within a 3 – 5 year period. The Foundation not only funds mainstream scientific research but also projects that combine integrative (complementary) therapies or botanical agents. These annual Medical Research Awards total $225,000 and are given over a three-year period.

In recent years, the Foundation has expanded its reach to include the funding of select pediatric oncology initiatives, music therapy programs, as well as international projects.

Gabrielle’s Angel Foundation has awarded grants totaling nearly $35 million in global giving and maintains its status as one of the largest non-governmental sources of grant support for blood cancer research in the nation.

Annual Request for Proposals

Our invitation-only grant process is sent out annually each spring to National Cancer Institute (NCI) designated institutions only. Please consult your institution to see if you are eligible to apply. Submissions are due to the Foundation office in August after which they undergo rigorous peer review by the Foundation’s Medical Advisory Board.

This panel of experts, led by Stephen D. Nimer, MD, Director of the Sylvester Comprehensive Cancer Center, selects only the nation’s most promising projects for funding. More than 80% of our grantees go on to obtain further funding thanks to early career support from Gabrielle’s Angel Foundation.

Determinations are made and all applicants notified by the first quarter of the year following application submission, if not sooner. 

While working on submissions, qualified candidates may download and reference these Frequently Asked Questions. The guidelines are the same for both our Conventional and Integrative applicants, however, please reference this additional information for all Integrative Medicine proposals

International Proposals

While we have funded research in the UK in years past, the Foundation is not currently accepting applications for consideration.


New 2020 Medical Research Awards Announced

The Foundation’s Medical Advisory Board has recently selected six of the nation’s top junior investigators to receive our three-year, $225,000 Medical Research Award. We are so proud to support these innovative projects and look forward to sharing updates about them!

Grantee: Dr. Brian Dalton, MD, Johns Hopkins University

Title of Grant: Dietary Serine Modulation as a Precision Nutrition Therapy for AML

 Description: Integrative cancer treatments incorporating diet are needed. We have found that certain patients with acute myeloid leukemia may benefit from a dietary intervention affecting the amino acid serine. We propose studies to better understanding and improve upon this intervention so that it can be used to help leukemia patients.

Grantee: Dr. Jamie Spangler, Johns Hopkins University

Title of Grant:       Engineered Natural Killer Cell Therapies Targeting Acute Myeloid Leukemia

Description: Acute myeloid leukemia (AML) is a highly prevalent form of blood cancer with extremely low survival rates. Therapies that activate the patient’s immune system to fight disease have been successful in many leukemias, but not AML. We will create a new immune-activating therapy that robustly and safely targets AML.

Grantee: Dr. Andrew Intlekofer, MSKCC

Title of Grant:       Elucidating and targeting IDH2 mutations in T cell lymphoma

Description: Drugs that target mutant forms of the metabolic enzyme isocitrate dehydrogenase 2 (IDH2) are a promising approach to treat some cancers. The proposed research will uncover how mutant IDH2 causes T cell lymphoma and determine whether inhibiting mutant IDH2 offers an effective way to treat this type of blood cancer.

Grantee: Dr. Nathan Singh, Washington University St. Louis

Title of Grant:       Role of co-stimulatory domains in CAR T cell dysfunction

Description: Cell-based immune therapies have demonstrated impressive success in the treatment of blood cancers, however most patients treated with available cellular immunotherapies are not cured. The goal of this proposal is to identify the molecular pathways responsible for failure of these therapies and design strategies to improve their efficacy.

Grantee: Dr. Shannon Elf, University of Chicago

Title of Grant:       Dissecting the role of the unfolded protein response in type 1 CALRmutated myelofibrosis

Description: The experiments proposed will help to answer why, among the two types of CALR mutations found in MPN patients, only one type causes myelofibrosis, the most deadly and difficult to treat disease among the three MPN types. This in turn will help us uncover new therapeutic options for CALR-mutated myelofibrosis.

Grantee: Dr. Yibin Yang, Fox Chase Cancer Center

 Title of Grant: Investigating the essential roles of Kelch-like family member KLHL11 in the pathogenesis of Anaplastic Large Cell Lymphoma and in normal T cells

Description: This project will seek to address the importance of a novel E3 ligase, KLHL11, in the pathogenesis of T cell lymphoma and in normal T cells, through a comprehensive and physiologically relevant fashion. Finishing this project will provide the foundation of targeting this enzyme as a therapeutic strategy in lymphoma.

Learn more about our Medical Research Award recipients & their proposed projects here. 

Collaborative Awards

In 2021, The Mark Foundation for Cancer Research partnered with the Gabrielle’s Angel Foundation for Cancer Research to fully support two of its Medical Research Awardees.

The awardees, Dr. Shannon Elf from the University of Chicago, and Dr. Yibin Yang from Fox Chase Cancer Center were announced at the Angel Foundation’s 25th Angel Ball on August 20th. Each researcher will receive $225,000 over a three-year period to support their blood cancer research. 

“We are so grateful to the Mark Foundation for fully supporting these two Medical Research Awards this year,” says Denise Rich, Founder of Gabrielle’s Angel Foundation for Cancer Research. “After a tough fundraising year in 2020, their support has allowed us to uphold our commitment to funding the best and brightest early career scientists focusing on blood cancer research. We are so thrilled to work together towards our common goal of curing cancer!” 

Read the full press release here. 

Grantee Breakthroughs

“We have fostered an entire generation of cancer researchers and fueled their scientific breakthroughs,” said Medical Advisory Board Chairman, Dr. Stephen Nimer. “The future of cancer research has never been brighter and we are helping lead the way.”